EdwardMWolinMD

Endocrine Cancer, Gastrointestinal Cancer, Hematologic Oncology

Director of the Center for Carcinoid and Neuroendocrine Tumors, Tisch Cancer Institute at Mount Sinai, Professor of Medicine, Medical Oncology at Icahn School of Medicine at Mount Sinai

Request Appointment

Overview of Dr. Wolin

Dr. Wolin is Director of the Center for Carcinoid and Neuroendocrine Tumors
at the Tisch Cancer Institute at Mount Sinai, and Professor of Medicine, Medical
Oncology, at the Icahn School of Medicine at Mount Sinai. The Center for Carcinoid and Neuroendocrine Tumors features robust research program, with clinical trials including immunotherapy, biologic agents, peptide receptor radionuclide therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, MET inhibitors, antiangiogenic drugs, and peptide receptor radiotherapy using both the somatostatin receptor and norepinephrine transporter as molecular targets.
Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor
Program at Montefiore Einstein Cancer Center. Previously, he worked for more than
two decades at Cedars-Sinai Medical Center in Los Angeles, where he founded
and directed the large Carcinoid and Neuroendocrine Tumor Program in that
institution, and subsequently directed the Neuroendocrine Tumor Program at University
of Kentucky. Dr. Wolin is Co-Medical Director for the Carcinoid Cancer Foundation
and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the
American Association for Cancer Research. He has published in many prestigious
journals, including the New England Journal of Medicine and Journal of Clinical
Oncology, and is a reviewer for numerous journals, including Journal of Clinical
Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The
Lancet Oncology.
Dr. Wolin earned his medical degree from Yale School of Medicine. He completed
both his residency in internal medicine and fellowship in medical oncology at
Stanford University Hospital. He was also a clinical fellow at the National Cancer
Institute of the National Institutes of Health. Dr. Wolin is board certified in Internal
Medicine and Medical Oncology.

Office
10 E 102nd St
New York, NY 10029
Book by Phone+1(415) 944-4167

Fax+1 212-423-0522

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1979
Clinical Center at the National Institutes of HealthFellowship, Clinical Associate , 1977
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1976
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1974 - 1975
Yale School of MedicineClass of 1974
Reed CollegeBA, Biology , 1970

Certifications & Licensure

OR State Medical License 2009 - Present
CA State Medical License 1975 - 2026
NY State Medical License 2015 - 2026
NJ State Medical License 2021 - 2025
KY State Medical License 2014 - 2016
IA State Medical License 2013 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient’s Choice Physician Award 2009, 2010. 2011, 2012
Excellence Award Healthnetwork Foundation Service, 2009
Member Sigma Xi Honorary Scientific Research Society, 1974
Member Phi Beta Kappa, 1970
Class of 1911 Prize – Most Outstanding Undergraduate Thesis Reed College, 1970
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease Start of enrollment: 2008 Apr 01
Completed
Phase 3
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) Start of enrollment: 2011 Aug 01
Completed
Phase 1
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
Completed
Phase 2
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2018 Oct 26
Active, not recruiting
Phase 3
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Start of enrollment: 2022 Mar 24
Active, not recruiting
Phase 3
Roles: Principal Investigator, Contact
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Start of enrollment: 2021 Dec 21
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

190 citations
Consensus on biomarkers for neuroendocrine tumour disease
Kjell Öberg, Irvin M. Modlin, Wouter W. de Herder, Marianne Pavel, David S. Klimstra
The Lancet. Oncology. 2015-09-01
99 citations
Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs
Simron Singh, Dan Granberg, Edward M. Wolin, Richard R.P. Warner, Maia Sissons
Journal of Global Oncology. 2017-02-01
1806 citations
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito, Catherine Lombard Bohas, Edward M. Wolin
The New England Journal of Medicine. 2011-02-10

Journal Articles

The ghost carcinoid in a patient with 120-fold elevated 5-HIAA.
Yu, R., Wolin, E, Endocr Pract, 1:1-6

Books/Book Chapters

Care of the Geriatric Patient.
Chapter: Cancer in the Geriatric Patient
Page 74 - 91Wolin, E.M., Ed. Steinberg, F.UThe C.V. Mosby Company
Surgical Oncology: A Multidisciplinary Approach to Difficult Problems.
Chapter: The Role of Adjuvant Therapy in Node-Negative Breast Cancer Patients-Commentary
Page 349 - 350Wolin, E.M., Ed. Silberman, H., Silberman, A.WArnold Publishing, Paris
Principles and Practice of Surgical Oncology.
Chapter: Commentary on Neuroendocrine Tumors of the Gastroenteropancreatic Axis
Page 799 - 800Wolin, E.M., Ed. Silberman, H., Silberman, A.WLippincott Williams and Wilkins

Abstracts/Posters

Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors.
Strosberg, J.R., Fisher, G.A., Benson, A.B., Malin, J.L., Anthony, L.B., Arslan, B., Gibbs, J.F., Greeno, E., Iyer, R.V., Kim, M.K., Maples, W., Philip, P.A., Wolin, E..., 2012 ASCO Annual Meeting, Chicago, IL
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2.
Wolin, E.M., Fazio, N., Saletan, S., Winkler, R.E., Panneerselvam, A., Kvols, L, 2011 ASCO Annual Meeting, Chicago
Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial.
Pommier, R.F., Wolin, E.M., Panneerselvam, A., Saletan, S., Winkler, R.E., Van Cutsem, E, J Clin Oncol, 29:suppl
31. Strosberg, J.R., Lincy, J., Winkler, R.E., Wolin, E.M., “Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomi...
31. Strosberg, J.R., Lincy, J., Winkler, R.E., Wolin, E.M, 2011 ASCO Annual Meeting, Chicago, IL
Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III R...
Baudin, E., Wolin, E.M., Castellano, D.E., Kaltsas, G., Lebrec, J., Tsuchihashi, Z., Klimovsky, J., Saletan, S., Yao, J.C., Gross, D, 2011 ASCO Annual Meeting, Chicago, IL
Systemic therapy of Neuroendocrine Tumors in 2011 and in the Future.
Wolin, E.M, World J Nucl Med, 10:51-52
Correlation Of PFS And Chromogranin A And 5-Hydroxyindoleacetic Acid Levels In Patients With Advanced Neuroendocrine Tumors: Phase III Radiant-2 Study Results.
Baudin, E., Castellano, D., Kaltsas, G., Gross, D., Lebrec, J., Tsuchihashi, Z., Klimovsky, J., Saletan, S., Yao, J., Wolin, E, 13th World Congress on Gastrointestinal Cancer, Barcelona, Spain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial (RADIANT-3) of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: Upda...
Strosberg, J.R., Wolin, E.M., Pommier, R., Lincy, J., Winkler, R., Yao, J, 2011 Gastrointestinal Oncology Conference, Arlington, VA
Correlation of Progression-Free Survival (PFS) with Early Response of Biomarkers Chromogranin A (CgA) and 5-Hhydroxyindoleacetic Acid (5-HIAA) Levels in Patients with ...
Wolin, E.M., Castellano, D., Kaltsas, G., Gross, D., Panneerselvam, A., Klimovsky, J., Saletan, S., Yao, J., Baudin, E, 4th Annual Meeting of the North American NeuroEndocrine Tumor Society, Minneapolis, MN
Updated Results From the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial (RADIANT-3) of Everolimus in Patients With Advanced Pancreatic Neur...
Wolin, E., Pommier, R., Lincy, J., Winkler, R., Yao, J, Am J Gastroenterol, 106:S59
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuro...
Yao, J.C., Hainsworth, J.D., Wolin, E.M., Pavel, M.E., Baudin, E., Gross, D., Ruszniewski, P., Tomassetti, P., Panneerselvam, A., Saletan, S., Klimovsky, J, 2012 Gastrointestinal Cancers Symposium, ASCO, San Francisco, CA
FDG-PET to predict outcome of patients with liver metastasis treated with Yttrium-90 radioembolization.
Zalom, M., Ih, G., Friedman, M., Wolin, E., Yu, R., Waxman, A, Society of Nuclear Medicine 2012 Annual Meeting, Miami Beach, FL
Long-term, Open-label Pasireotide in Patients With Neuroendocrine Tumors Experiencing Carcinoid Symptoms: Case Presentations.
Wolin, E.M., Giannone, V., Mohideen, P, ESMO 14th World Congress on Gastrointestinal Cancer, Barcelona, Spain
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III ...
Shah, M.H., Ito, T., Lombard-Bohas, C., Wolin, E.M., Van Cutsem, E., Sachs, C., Winkler, R.E., Lincy, J., Hobday, T.J., Yao, J.C, 2011 ASCO Annual Meeting, Chicago, IL
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuro...
Yao, J.C., Hainsworth, J.D., Wolin, E.M., Pavel, M.E., Baudin, E., Gross, D., Ruszniewski, P., Tomassetti, P., Panneerselvam, A., Saletan, S., Klimovsky, J, 2012 ASCO Annual Meeting, Chicago, IL
Using the Modified RAND/UCLA Delphi Process to Produce Treatment Consensus in Unresectable Midgut Gastrointestinal Neuroendocrine Tumors.
Strosberg, J.R., Fisher, G., Benson, A.B., Malin, J.L., Anthony, L., Arslan, B., Gibbs, J.F., Greeno, E., Iyer, R., Kim, M.K., Maples, W., Philip, P.A., Wolin, E., Che..., Value Health, 15:A228-A229
An Expert Panel Consensus on Medical Treatment of Non-Midgut Unresectable Neuroendocrine Tumors.
Benson, A.B., Strosberg, J.R., Fisher, G., Malin, J.L., Anthony, L., Arslan, B., Gibbs, J.F., Greeno, E., Iyer, R., Kim, M.K., Maples, W., Philip, P.A., Wolin, E., Che..., Value Health, 15:AA229
Expert Panel Consensus Statements on the Medical Treatment of Unresectable Pancreatic Neuroendocrine Tumors.
Wolin, E, 94th Annual Meeting of The Endocrine Society - ENDO 2012, The Endocrine Society, Houston, TX
Long-term, Open-label Pasireotide in Patients With Neuroendocrine Tumors Experiencing Carcinoid Symptoms: Case Presentations.
Wolin, E., Giannone, V., Mohideen, P, ESMO 14th World Congress on Gastrointestinal Cancer, Barcelona, Spain
Expert Panel Consensus Statements on the Medical Treatment of Unresectable Pancreatic Neuroendocrine Tumors.
Fisher, G., Strosberg, J.R., Benson, A.B., Malin, J.L., Anthony, L.B., Arslan, B., Gibbs, J.F., Greeno, E., Iyer, R., Kim, M.K., Maples, W., Philip, P.A., Wolin, E., C..., The Endocrine Society’s 94th Annual Meeting and Expo, Houston, TX, USA
There a Role for Liver Transplantation in Treatment of Metastatic Neuroendocrine Tumors?
Annamalail, A., Menon, V., Puril, V., Bresee, C., Leong, T., Wolin, E., Nissen, N., Colquhoun, S, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA
Open-label Everolimus in Patients With Pancreatic Neuroendocrine Tumors: Two Case Presentations From RADIANT-3.
Wolin, E, 2012 Gastrointestinal Oncology Conference, International Society of Gastrointestinal Oncology, Arlington, VA
An Expert Panel Consensus on Medical Treatment of Non-Midgut Unresectable Neuroendocrine.
Benson, A.B., Strosberg, J.R., Fisher, G.A., Malin, J.L., Anthony, L.B., Arslan, B., Gibbs, J.F., Greeno, E., Iyer, R.V., Kim, M.K., Maples, W.J., Philip, P.A., Wolin,..., North American Neuroendocrine Tumor Society Annual Meeting, San Diego, CA
Expert Panel Consensus Statements on the Medical Treatment of Unresectable Pancreatic Neuroendocrine Tumors.
Fisher, G.A., Strosberg, J.R., Benson, A.B., Malin, J.L., Anthony, L.B., Arslan, B., Gibbs, J.F., Greeno, E., Iyer, R.V., Kim, M.K., Maples, W.J., Philip, P.A., Wolin,..., North American Neuroendocrine Tumor Society Annual Meeting, San Diego, CA
Medical Treatment Consensus in Unresectable Midgut Gastrointestinal Neuroendocrine Tumors.
Strosberg, J.R., Fisher, G.A., Benson, A.B., Malin, J.L., Anthony, L.B., Arslan, B., Gibbs, J.F., Greeno, E., Iyer, R.V., Kim, M.K., Maples, W.J., Philip, P.A., Wolin,..., American Neuroendocrine Tumor Society Annual Meeting, San Diego, CA
Join now to see all

Lectures

Evaluation and Management of Metastatic Neuroendocrine Tumors of the Pancreas and Small Intestine.
Fairmont-Miramar Hotel, Santa Monica, CA
Neuroendocrine Tumor Basics – What Every Patient Needs to Know.
Cedars-Sinai Medical Center, Los Angeles, CA
Neuroendocrine Tumors.
Cedars-Sinai Medical Center, Los Angeles, CA
The Importance of Somastostatin Analogs.
Carcinoid NeuroEndocrine Tumour Society Canada, Vancouver, BC, Canada
Multi Modality Patient Management Discussions.
Carcinoid NeuroEndocrine Tumour Society Canada, Vancouver, BC, Canada
Chemotherapy and Biologic Therapy. What’s new in 2010.
Carcinoid NeuroEndocrine Tumour Society Canada, Vancouver, BC, Canada
Interactive Multidisciplinary Neuroendocrine Case Studies.
Cedars-Sinai Medical Center, Los Angeles, CA
Latest treatment options for carcinoid and neuroendocrine tumor patients.
Cedars-Sinai Medical Center, Los Angeles, CA
Lecture to Surgical Residents on MEN-1.
Cedars-Sinai Medical Center, Los Angeles, CA
Is a Clinical Trial Right for You? Clinical Trials available for neuroendocrine tumor
Cedars-Sinai Medical Center, Los Angeles, CA
Carcinoid Heart Disease.
Cedars-Sinai Medical Center, Los Angeles, CA, 2009
Pancreatic Neuroendocrine Tumors.
Cedars-Sinai Medical Center, Los Angeles, CA
Atiprimod and Pasireotide.
Cedars-Sinai Medical Center, Los Angeles, CA
New Developments in NET from the American Society of Clinical Oncology.
Hematology/ Oncology Grand Rounds – Cedars-Sinai Medical Center, Los Angeles, CA
Cancer Prevention/Early Detection.
Interactive Videoconference for Women, Mexico City
Atiprimod and Everolimus (RAD001) – Novel Treatments for Neuroendocrine Tumors.
Erasmus University, Rotterdam, Netherlands
Carcinoid Heart Disease: Diagnosis, Prognosis, and Treatment.
Caring For Carcinoid Foundation Symposium, Los Angeles, CA
New Therapies for Neuroendocrine Tumor Patients: Approved and in Development.
Cedars-Sinai Medical Center and the Caring for Carcinoid Foundation, Intercontinental Hotel, LA
Advances in Therpay of Carcinoid Neuro-Endocrine Tumors.
Hematology/Oncology Grand Rounds – Cedars-Sinai Medical Center, Los Angeles, CA
New Therapeutic Options for Neuro-Endocrine Tumors And Advances in Personalized Patient Care.
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
What’s new in Chemotherapy/Biologic response modifier therapy of NETS.
Carcinoid Cancer Awareness Network – Astor Crown Plaza, New Orleans, LA
Expert Panel Consensus Statements on the Medical Treatment of Unresectable Pancreatic Neuroendocrine Tumors.
94th Annual Meeting of The Endocrine Society - ENDO 2012, The Endocrine Society, Houston, TX
Introduction to Centres of Excellence – Challenges Overcome and Challenges Ahead.
Carcinoid NeuroEndocrine Tumour Society Canada, Ottawa, ON, Canada
Exciting new developments in systemic therapy of NeuroEndocrine Tumours: somatostatin analogues, biological agents including everolimus and sunitinib, and other system...
Carcinoid NeuroEndocrine Tumour Society Canada, Ottawa, ON, Canada
Multidisciplinary Tumour Board (Part 1) – two patient case profiles.
Carcinoid NeuroEndocrine Tumour Society Canada, Ottawa, ON, Canada
Join now to see all

Other

In Her Own Time.
Wolin, E, Dir. Lynne Littman
Steve Jobs Death brings Spotlight to Rare Type of Pancreatic Cancer.
Wolin, E, KABC News. ABC
KABC, Los Angeles
Interview with Dr. Wolin about the shark cartilage controversy.
Wolin, E, KNBC News. NBC
KNBC, Los Angeles
Interview with Dr. Wolin about Antioxidant Vitamins.
Wolin, E, KNBC News. NBC
KABC, Los Angeles
Interview with Dr. Wolin about Lumpectomy for Breast Cancer.
Wolin, E, KNBC News. NBC
KABC, Los Angeles
Interview with Dr. Wolin about a Test for Colon Cancer.
Wolin, E, KNBC News. NBC
KABC, Los Angeles
Interview with Dr. Wolin about Taxol for Treatment of Ovarian Cancer.
Wolin, E, KNBC News. NBC
KABC, Los Angeles
Heather Farr Story.
Wolin, E, CNN-TV
Interview. Weekend Gallery.
Wolin, E, WB. KTLA
Los Angeles
Interview with Dr. Wolin about Diet Affecting Colon Cancer.
Wolin, E, KABC News. ABC
KNBC News. NBC
Interview with Dr. Wolin about Pediatric Visualization in Cancer.
Wolin, E; Dr. Bruce
KNBC, Los Angeles
Cancer Survivors Program about the Killions.
Wolin, E, KCAL News. CBS
KCAL, Los Angeles
Interview with Dr. Wolin – Breast Cancer.
Wolin, E
Daytime Dialogue. KWNY, 1986; KTTV, Los Angeles
Interview about Colon Cancer.
Wolin, E, Insight. CBS
KRTH, Los Angeles
Metastatic Neuroendocrine Tumors.
Wolin, E, Gastrointestinal Cancer: Part 2. Audio-Digest Gastroenterology, 24:9
Join now to see all

Press Mentions

The Carcinoid Cancer Foundation and PlatformQ Health to Host Live, Online Education on Carcinoid SyndromeFebruary 23rd, 2017
Ipsen Announces Data Presentations of Cabozantinib (Cabometyx™), Lanreotide (SomatulineSeptember 27th, 2016
) Et Le Telotristat éthyle* Lors Du Congrès 2016 De L’European Society for Medical Oncology (ESMO)September 27th, 2016

Insurance Accepted

Aetna Choice POS II
BCBS Alabama PPO
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Harvard Pilgrim HMO
Health Net California Large Group PPO
Health Net HMO - Employer Group
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment